including age, digital rectal examination (DRE) finding, prostate volume, the number of cores taken during biopsy, PSA level, overall cancer detection rate, and the Gleason score pattern were reviewed. Prostate volume was estimated by transrectal ultrasound using a prolate ellipsoid volume calculation of height times width times length times 0.52. PSAD was calculated by dividing serum PSA concentration by the prostate volume.
model 4, PSA, PSAD, presence of abnormal DRE and age were included in the logistic regression analyses. All statistical analyses were performed using SPSS version 20.0 (IBM Corp., Armonk, NY).
RESULTS
Data from a total of 2606 Chinese men who underwent TRUS-PB from year 2000 to 2013 was retrieved. The mean age of the cohort was 68.4 ± 8.0 years. Among the patients who underwent TRUS-PB, 23.9% of them (623 patients) had abnormal digital rectal examination finding. The mean estimated prostate volume upon transrectal ultrasound was 44.8 ± 23.7 ml. The mean number of cores taken during biopsy was 10.1 ± 1.6. The mean PSA level was 71.0 ± 462.1 ng ml −1 . The mean PSAD was 2.12 ± 15.3 ng ml −1 cc −1
. The overall cancer detection rate was 27.6%. For patients with confirmed prostate cancer, 37.7% of them had Gleason score of 2-6, 21.2% had Gleason score of 7 and 41.1% had Gleason score of 8-10 ( Table 1) .
The ROC curves of PSA and PSAD for prostate cancer detection were analyzed (Figure 1) . The AUC was 0.770 for PSA (P < 0.001) and 0.823 for PSAD (P < 0.001). For the different PSA cut-off levels ( Further logistic regression analyses for prostate cancer detection on TRUS-PB were performed to determine the significance of PSA cut-off at 4.5 ng ml −1 and PSAD cut-off at 0.12 ng ml −1 cc −1 ( 
DISCUSSION
The investigation on tissue-specific antibodies in the human prostate first started in 1969 by Ablin et al. 11 Nadji et al. later characterized PSA as a potential marker for prostatic neoplasms. 12 The discovery of PSA has led revolutionary changes in early prostate cancer diagnosis. Catalona et al. conducted a number of important studies on the utility of PSA and PSAD for early prostate cancer detection, 3, 5, 13 and the use of PSA and PSAD has become widely accepted. However, the previous reports were largely based on Caucasians. Whether the results can be applied to Asians remained as an area of controversy. Our TRUS-PB database contained data of all patients who underwent TRUS-PB for suspected prostate cancer in our center from year 2000 onwards. While the decision on TRUS-PB was often made in an individualized approach, the common indications of TRUS-PB in our database were PSA level of >4.0 ng ml −1 and any presence of abnormal DRE finding. We conducted this study to provide Chinese-specific data for investigating the performances of PSA and PSAD in Chinese men.
A total of 2606 Chinese patients were included in our study. PSA and PSAD had good performances in prostate cancer detection with an AUC of 0.770 for PSA (P < 0.001) and 0.823 for PSAD (P < 0.001). Concerning the different PSA cut-off levels, a PSA level of 4.5 ng ml −1 had a sensitivity of 94.4%, specificity of 14.1%, PPV of 29.5% and NPV of 86.9%, and a PSA level of 5.5 ng ml −1 had a sensitivity of 89.3%, specificity of 31.6%, PPV of 33.2% and NPV of 88.6%. In the study by Catalona et al., 5 a PSA cut-off value of 4.0 ng ml −1 had a sensitivity of 78.6% and specificity of 45.8%. With a sensitivity of around 80%, this corresponds to a PSA cut-off value of 7.0 ng ml −1 in our study on Chinese men with a sensitivity of 79.4% and specificity of 50.7%. In the study by Sun et al. 14 at a PSA level of 4.0 ng ml −1 , the sensitivity was 61.3%-71.3% compared to 97.6% in our study, while the specificity was 85.2%-97.7% compared to 7.3% in our study. The optimal PSA level for considering TRUS-PB in the Chinese population appeared to be very different from that in the Caucasians. The reason why there was such a major difference could not be simply explained by a lower prostate cancer incidence in Chinese men. As the results were based on specified PSA levels, unless there were confounding factors which were more prevalent in Chinese men that might cause falsely elevated PSA, otherwise the number of benign and cancer cases should be proportionate. On multivariate logistic regression analyses, PSA cut-off of 4.5 ng ml −1 was a significant predictor of prostate cancer detection (OR 1.61, 95% CI 1.05-2.45, P = 0.029) after adjusting for PSAD, presence of abnormal DRE and age. While further studies are needed to investigate for potential differences in the natural history and aggressiveness of prostate cancer in the Chinese population, a PSA level of 4.5 ng ml −1 appeared to be an appropriate cut-off level for Chinese men to consider TRUS-PB with a reasonable sensitivity of 94.4%. In our cohort, with reference to a PSA level of 4.5 ng ml −1 , TRUS-PB for all men with PSA of more than 4 ng ml −1 will lead to an increase in 151 biopsies (+6.57%), while detecting 23 more prostate cancers (+3.39%).
Being first proposed by Benson et al. 7 to distinguish between benign prostatic hypertrophy and prostate cancer, a PSAD cut-off of 0.15 ng ml −1 cc −1 was recommended in earlier studies. 15 However, Lujan et al. 16 showed that when a PSAD cut-off of 0.15 ng ml −1 cc −1 was used, up to 30.6% of prostate cancer would be missed and suggested that a lower PSAD cut-off should be used. In our cohort, a PSAD of 0.12 ng ml −1 cc −1 had a sensitivity of 94.5%, specificity of 26.6%, PPV of 32.8%, and NPV of 92.7%, and a PSAD of 0.15 ng ml −1 cc −1 had a sensitivity of 89.7%, specificity of 41.7%, PPV of 36.9%, and NPV of 91.4%. In the study by Catalona et al. 5 a PSAD of 0.10 ng ml −1 cc −1 had a sensitivity of 78.8% and a specificity of 46.9%. With a sensitivity of around 80%, this corresponds to a PSAD cut-off While PSA is organ-specific but not tumor-specific, its serum level may be altered by various confounding conditions including urinary tract infection, prostatitis, urinary retention, etc. Similarly, PSAD depends on the prostate volume size, which may in turn be proportionate to one's body weight, body height, and body mass index. Unfortunately, we were unable to retrieve such parameters from our database. The major limitation in our study would be the lack of evaluation of potential confounding factors, which may affect PSA and PSAD.
To our knowledge, this is the largest study investigating the performances of PSA and PSAD at different cut-off levels in the Chinese population. Our results provided important information in deciding when to perform TRUS-PB in Chinese men. While there is a lack of data concerning the natural history and aggressiveness of prostate cancer in the Chinese population, PSA of 4.5 ng ml −1 and PSAD of 0.12 ng ml −1 cc −1 appeared to be appropriate levels for Chinese men to consider TRUS-PB. This recommendation was based on a near 95% sensitivity for both PSA (94.4% sensitivity) and PSAD (94.5% sensitivity). While a PSA cut-off value of 4.0 ng ml −1 and a PSAD cut-off value of 0.15 ng ml −1 cc −1 are often used to determine which patient to consider TRUS-PB in our locality, further studies are necessary to investigate the effect of increasing the PSA cut-off value from 4.0 to 4.5 ng ml −1 , and decreasing the PSAD cut-off value from 0.15 to 0.12 ng ml −1 cc −1
. Balance has to be made to avoid excessive unnecessary biopsies while detecting most if not all of the clinically significant prostate cancers.
